← Back to Search

PET/MRI Brain Imaging for Alzheimer's Disease (PiB ADC Trial)

Phase 2

Recruiting

Led By Jonathan McConathy, MD

Research Sponsored by University of Alabama at Birmingham

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 5 years

Awards & highlights

No Placebo-Only Group

Summary

This trial uses a special imaging dye to detect harmful protein build-up in the brains of participants from the UAB Alzheimer's Disease Center. The study aims to understand how these brain changes relate to race, vascular risk factors, and cognitive health. The dye helps make these harmful proteins visible in brain scans.

Who is the study for?

This trial is for participants already enrolled in the UAB Alzheimer's Disease Center study. It's focused on those who can undergo PET/MRI scans and do not have severe dementia that would prevent participation. Women of childbearing potential must test negative for pregnancy.

What is being tested?

The study aims to measure amyloid deposits in the brain using a PET tracer called [C-11]PiB. It will explore how race and vascular risk factors interact with these amyloid levels and cognitive status.

What are the potential side effects?

Since this is an imaging study, side effects are minimal but may include discomfort from lying still during scanning, reactions to contrast agents used (if any), or claustrophobia inside the scanner.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Amyloidosis

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: [C-11]PiB-PET/MRIExperimental Treatment1 Intervention

All participants in this study will undergo an amyloid-PET imaging using the tracer \[C-11\]PiB with a simultaneous PET/MRI system. The \[C-11\]PiB dosage is 300-670 MBq (8 - 18 mCi) given intravenously, and the PET/MRI imaging time is approximately 60 min.

Do I qualify?Apply below to find out